Matching placebo for selinexor

DRUG2 trials

Sponsors

Karyopharm Therapeutics Inc

Conditions

Endometrial Cancer

Phase 3

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

CompletedNCT03555422

Karyopharm Therapeutics IncEndometrial Cancer

Start: 2018-01-05End: 2025-04-03Updated: 2026-04-13

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Active, not recruitingNCT05611931

Karyopharm Therapeutics IncEndometrial Cancer

Start: 2023-04-18End: 2028-01-01Updated: 2026-08-27

Related Papers

Post-hoc analysis evaluating selinexor maintenance therapy in patients with <i>TP53</i> wt endometrial cancer: Progression-free survival by clinical factors in the ENGOT-EN5/GOG-3055/SIENDO study.

Journal of Clinical Oncology2025-05-28

ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.

2024-08-055 citations

Exporting nuclear export inhibitors from hematologic to solid tumour malignancies

Clinical and Translational Discovery2024-07-29

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.

2024-06-0317 citations

Phase 3 dose selection for selinexor in <i>TP53</i>wt endometrial cancer based on exposure-response analysis.

Journal of Clinical Oncology2024-06-01

187 Selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: long-term follow up of efficacy and safety subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

2024-03-012 citations

PO006LBA/#1520 Selinexor maintenance for patients with TP53WT advanced or recurrent endometrial cancer: long-term follow up of efficacy and safety subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

2023-11-011 citations

TP010/#397 ENGOT-EN20/GOG-3083/XPORT-EC-042 a phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma

2023-11-01

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

Journal of Clinical Oncology2023-09-0562 citations

#264 Long-term follow up of selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: a pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study

2023-09-013 citations

#265 ENGOT-EN20/GOG-3083/XPORT-EC-042 a phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma

2023-09-01

Long-term follow up of selinexor maintenance in patients with <i>TP53</i>wt advanced or recurrent endometrial cancer: A pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study.

Journal of Clinical Oncology2023-07-203 citations

ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.

Journal of Clinical Oncology2023-06-013 citations

Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.

Journal of Clinical Oncology2022-06-0111 citations

SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.

Journal of Clinical Oncology2021-05-208 citations

SIENDO/ENGOT-EN5: A randomized phase III trial of maintenance with selinexor/placebo after combination chemotherapy in patients with advanced or recurrent endometrial cancer.

Journal of Clinical Oncology2020-05-20